BIOCELL Journal Vol.48, No.12, 2024 is now available online

BIOCELL Journal Vol.48, No.12, 2024 is now available online

The December 2024 issue (Volume 48, Issue 12) of BIOCELL is now available online. This issue features three editor-selected review articles that spotlight cutting-edge advancements in key areas of research, including targeting the cholangiocarcinoma microenvironment, the pathological interplay between type 2 diabetes mellitus and Parkinson’s disease, and the therapeutic potential of targeting the cancer cell cycle. Below is a detailed overview of the highlighted articles in this issue. We hope these insights into the latest developments in the field provide valuable perspectives and practical references for your research. We warmly welcome your readership and feedback.

1.Emerging pharmaceutical therapies for targeting cholangiocarcinoma microenvironment and chemokine pathways

ARMAND N. YAZDANI, MICHAELA PLETSCH, ABRAHAM CHORBAJIAN, DAVID ZITSER, VIKRANT RAI*

Figure 2: General principle of innate immune response. This figure displays different cells of the innate immune system, such as macrophages, neutrophils, and dendritic cells, and the process by which the innate immune system acts to recognize pathogens to create a host immune response. This process involves a sensor that leads to cell production of pro-inflammatory cytokines and the migration of effector cells (neutrophils, macrophages, T cells, and B cells) to inflammation. While this often occurs in infection, it can also occur within tumor microenvironments in response to pro-inflammatory signaling. The figure is created using BioRender.

Mixed cholangiocarcinoma is a rare and highly aggressive form of biliary epithelial cell neoplastic proliferation, accounting for up to 20% of primary liver cancers. It is the second most common primary liver malignancy, with a five-year survival rate of less than 10% at diagnosis, and it is closely associated with various inflammatory diseases. Recent discoveries and insights into the tumor microenvironment have opened new avenues for targeted therapies in cholangiocarcinoma. Specifically, novel pharmaceuticals, including cell-based vaccines, tumor-associated neutrophils, and hepatic stellate cells, show promise as potential therapeutic targets.

This review explores emerging pharmaceutical therapies aimed at the cholangiocarcinoma microenvironment and the chemokine pathways involved in its pathogenesis, while also providing a risk-benefit analysis of the proposed treatment options. Future research should focus on optimizing the efficacy of tumor protein vaccines such as MUC1 and WT1, particularly by investigating the potential of combining these vaccines with other immunotherapeutic strategies, such as immune checkpoint inhibitors.

2.Unraveling the molecular crossroads: T2DM and Parkinson’s disease interactions

TINGTING LIU#, XIANGRUI KONG#, JIANSHE WEI*

Figure 6: T2DM is negatively related to PD. Nicotine leads to dysfunction of pancreatic β cells and exacerbates IR, while inhibiting inflammatory factors reduces PD symptoms. The Sirtuins family inhibits inflammation and fatty acid oxidation, reduces T2DM, activates inflammatory factors, causes oxidative stress, and exacerbates α-syn aggregation, leading to the occurrence of PD. Red represents inhibition, green represents activation.

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by persistent hyperglycemia. In recent years, an increased risk of Parkinson’s disease (PD) has been observed among individuals with T2DM. However, the molecular mechanisms underlying the interaction between T2DM and the pathogenesis of PD remain not fully elucidated. This review summarizes some of the shared pathophysiological mechanisms, including genetic risk factors, hyperglycemia, insulin resistance (IR), inflammation, mitochondrial dysfunction, oxidative stress, autophagy, and advanced glycation end products (AGEs), which independently or synergistically contribute to the onset and progression of both T2DM and PD. Additionally, the review compiles studies investigating the relationship between T2DM and PD, which may provide new insights for alternative therapeutic strategies for both diseases.

3.Targeting cell cycle regulators: A new paradigm in cancer therapeutics

GARIMA SINGH#, SONIKA KUMARI SHARMA#, NEELU MISHRA, AASTHA SONI, MANSHI KUMARI, SAMARENDRA KUMAR SINGH*

Graphic Abstract

Recent in-depth studies on cancer cell susceptibilities have revealed the therapeutic potential of selectively targeting the cell cycle in malignant cells. This review focuses on the major cell cycle dysregulations in cancer cells and introduces the latest developments in anticancer agents targeting cell cycle factors, which are either in clinical practice or in clinical trials. Given the increasing drug resistance observed in cancer patients, the article also explores mechanistic insights into potential therapeutic strategies targeting these cell cycle factors. Additionally, the review outlines the future research directions required to develop new therapies and optimize existing ones for maximum efficacy.

About the journal

BIOCELL is an international, peer-reviewed, open access journal on molecular and celluar biosciences. It publishes papers of the highest quality from all areas of cell biology, encouraging those that shed light on the mechanisms underlying fundamental cell biological processes, which creates an indispensable reading and publishing area for all scientists, researchers, clinicians, and teachers in colleges and universities. The journal welcomes high quality?original research articles, review papers, communications, perspectives, commentaries, etc. to stimulate the interest of the broad readership of the journal. Topics of interests include but are not limited to:

  • Cellular?Biochemistry
  • Structural & Molecular Biology
  • Cellular/Molecular?Biology, Immunology, Pathology & Neurobiology
  • Cell Signaling
  • Regenerative Biology & Stem Cells
  • Cancer Biology
  • RNA Biology
  • Genomics,?Transcriptomics,?Proteomics &?Metabolomics
  • Plant Molecular & Cellular Biology

?? Submit Now

Why Publish with Us:

  • Swift and rigorous peer-review process.
  • Selected articles with open access publication.
  • Online-first publishing for instant accessibility.

Contact Us:

Office Hours: 9:00-17:00 (UTC -8:00)

[email protected]

要查看或添加评论,请登录

Tech Science Press的更多文章

社区洞察

其他会员也浏览了